OncLive TV

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

Courtney DiNardo, MD, MSCE, iscusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory follicular lymphoma.

Fred Saad, MD, FRCS, discusses the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Hun Ju Lee, MD, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

William K. Kelly, DO, discusses results from a phase 1b dose-finding study evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.

Benjamin Leon Musher, MD, discusses immunotherapy versus TKIs in hepatocellular carcinoma.

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Javier Cortes, MD, PhD, discusses updated progression-free survival data from the phase 3 KEYNOTE-355 study with pembrolizumab plus chemotherapy in previously untreated patients with locally recurrent, inoperable or metastatic triple-negative breast cancer.

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Naveen Pemmaraju, MD, discusses the challenges of targeting TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Daniel Moreira, MD, discusses the rationale for launching the Global COVID-19 Observatory and Resource Center for Childhood Cancer.

Konstantin Zakashansky, MD, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Hun Ju Lee, MD, discusses the mechanism of action of the investigational ROR1 inhibitor cirmtuzumab in combination in mantle cell lymphoma and chronic lymphocytic leukemia.

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Sattva Neelapu, MD, discusses the mechanism of action of ALLO-501 when paired with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Hun Ju Lee, MD, an associate professor of medicine in the Department of Lymphoma & Myeloma and the Jessica and Jeffrey Brue Endowed Professor of Lymphoma Research at The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of the investigational ROR1 inhibitor cirmtuzumab in combination in mantle cell lymphoma and chronic lymphocytic leukemia.

Rogerio C. Lilenbaum, MD, discusses the promising future direction of immunotherapy in patients with advanced lung cancer.

Elizabeth M. Swisher, MD, discusses results from the phase III VELIA/GOG-3005 trial in ovarian cancer.

Mohammad Maher Abdul-Hay, MD, discusses the use of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) to guide transplant eligibility in acute lymphoblastic leukemia (ALL).